Business
Why the Immutep (ASX:IMM) share price is up 6% today
The Immutep Ltd (ASX: IMM) share price is soaring in early-afternoon trade. This comes after the company announced a second clinical trial collaboration with subsidiaries of Merck & Co. (MSD). At the time of writing, the biotechnology company’s shares are up 5.97% to 36 cents.
New Phase 2b trial
The Immutep share price is on the move as investors have been rallying up on the positive news.
According to its release, Immutep advised that it has entered a second clinical trial collaboration and supply agreement with MSD. This will see Immutep commence a new Phase 2b trial, named TACTI-003 using first-line head and neck squamous cell carcinoma (HNSCC) patients.
HNSCC is an aggressive life-threatening cancer that affects either the…
-
General24 hours agoUK deputy prime minister Angela Rayner resigns over property tax error
-
Business20 hours agoWall Street analysts say to buy one, but think the other is overvalued
-
General23 hours agoOldest member of British royal family, Katherine, Duchess of Kent, dies aged 92
-
Noosa News15 hours agoBrisbane city acquires 20 hectares of public land through post-floods property buyback scheme